

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		09675323	
	Filing Date		2000-09-28	
	First Named Inventor		Henry Lardy	
	Art Unit		1623	
	Examiner Name		Elli Peselev	
	Attorney Docket Number		208.3A2	

U.S. PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S. PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number	09675323
	Filing Date	2000-09-28
	First Named Inventor	Henry Lardy
	Art Unit	1623
	Examiner Name	Elli Peselev
	Attorney Docket Number	208.3A2

/E.P./	1	JAIN, A., et al., <u>Compass: Predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark</u> , J. Med. Chem., 1994, pps 2315-27, 37	<input type="checkbox"/>
/E.P./	2	LARDY, H., et al., <u>Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone</u> , Steroids, 1998, pps.158-65, 63	<input type="checkbox"/>
/E.P./	3	LOUGHNEY, D., et al., <u>A comparison of progestin and androgen receptor binding using the CoMFA technique</u> , J. Computer-Aided Molecular Design, 1992, pps. 569-81, 6	<input type="checkbox"/>
/E.P./	4	MARWAH, P., et al., <u>C10-steroids as androgen receptor modulators: design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonist</u> , Bioorg & Med. Chem., 2006, pps. 5933-47, 14	<input type="checkbox"/>
/E.P./	5	WALLER, C., et al., <u>Three dimensional quantitative structure activity relationships for androgen receptor ligands</u> , Tex. and Applied Pharmacology, 1996, pps. 219-37, 137	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE


Examiner Signature	/Elli Peselev/	Date Considered	04/12/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 208.3A	APPLICATION NO. 09/675,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT DEC 08 2003 (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT H. L. Lardy and P. Marwa	
		FILING DATE September 28, 2000	GROUP 1623



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CP	3,053,865	9/11/62	Taub et al.			
CP	3,124,571	5/10/64	Ringold et al.			
CP	3,128,375	3/24/64	Ringold et al.			
CP	3,277,124	10/4/66	Marshall			
CP	3,247,300	2/11/69	Sarett et al.			
CP	3,733,318	5/15/73	Marx			
CP	3,862,193	1/21/75	Hirsch			
CP	3,917,831	11/4/75	Grunwell et al.			
CP	3,944,576	3/16/76	van den Broek et al.			
CP	3,968,713	6/29/78	Hofmeister et al.			
CP	3,983,144	9/28/76	Leemhuis			
CP	3,998,860	12/21/76	Brown et al.			
CP	4,039,669	8/02/77	Beyler, et al			
CP	4,220,599	9/2/80	van der Vees			
CP	4,292,251	9/29/81	Overbeek			
CP	4,329,296	5/11/82	Tax			
CP	5,362,720	11/8/94	Labrie			
CP	5,502,183	3/26/96	Andrews, et al.			
CP	5,681,984	10/28/97	Ashton et al.			
CP	5,872,114	2/16/99	Labrie			
CP	6,150,336	11/21/00	Deninno			11/21/97
CP	6,630,453	10/7/03	Holick et al.			5/4/99

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CP	09/535,675	Ahlem, et al			
CP	09/820,483	Ahlem, et al			
CP	10/087,929	Ahlem, et al			
CP	10/319,358	Ahlem, et al			

EXAMINER	/Elli Peselev/	DATE CONSIDERED	04/12/2007
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO. 208.3A	APPLICATION NO. 09/675,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
DEC 08 2003			
(USE SEVERAL SHEETS IF NECESSARY)			
O P E R A T I O N S P A T E N T & T R A D E M A R K T E S T I C K		APPLICANT H. L. Lardy and P. Marwa	FILING DATE September 28, 2000
			GROUP 1623

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	DOCUMENT SERIAL NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CJ	10/329,065	Ahlem, et al			
CJ	10/602,330	Ahlem, et al			
CJ	10/606,524	Ahlem, et al			
CJ	10/607,035	Ahlem, et al			
CJ	10/607,415	Ahlem, et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
CJ	I. M. Thompson et al., New Engl. J. Med. The Influence of Finasteride on the Development of Prostate Cancer. 349:215-224, 2003

EXAMINER	/Elli Peselev/	DATE CONSIDERED	04/12/2007
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
(USE SEVERAL SHEETS IF NECESSARY)	

ATTY. DOCKET NO.
HOLISED.063AAPPLICATION NO.
09/675,323APPLICANT
LARDY, ET AL.FILING DATE
September 28, 2000

GROUP

AUG 20 2002

RECEIVED

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
Gr	5,387,583	2/7/95	Loria			
Gr	5,075,464	12/24/91	Blohm			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
Gr	WO 99/63973	12/16/99	PCT				
Gr	WO 97/37682	10/16/97	PCT				
Gr	WO 95/07926	3/23/95	PCT				
Gr	EP 0 383 128	4/11/90	Europe				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
Gr	Valentina Gatto, et al., "Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptor", <i>Oncology Reports</i> , vol. 5, pages 241-243 (1998)
Gr	Reinhard Hackenberg, et al., "Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3beta, 17beta-diol in human mammary cancer cells", <i>J. Steroid Biochem. Molec. Biol.</i> , vol. 46, no. 5, pages 597-603 (1993)

EXAMINER	Gr. Lekile	DATE CONSIDERED	4-12-2007
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			